Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Marc de Garidel, an experienced leader in the biopharma sector, was appointed CEO in 2023 to lead Abivax as it moves towards commercialization of its lead drug candidate, obefazimod, currently tested in phase 3 trials for the treatment of adults with moderately to severely active ulcerative colitis (UC). I recently talked with him about leadership and lessons he has learned over his career.